氨磺必利与利培酮治疗精神分裂症临床分析

A control study of amisulpride vs. risperidone in the treatment of schizophrenia

目的比较氨磺必利与利培酮治疗精神分裂症的临床疗效及安全性。方法将60例精神分裂症患者随机分为两组，每组30例，分别口服氨磺必利、利培酮治疗，观察6个月。于治疗前后采用阳性与阴性症状量表评定临床疗效，并比较两组不良反应发生状况。结果治疗后两组阳性与阴性症状量表评分均较治疗前显著降低（P〈0．01），氨磺必利组显著低于利培酮组（P〈0．05）；氨磺必利组不良反应发生率为13．3％，利培酮组为36．7％，两组比较差异无显著性（P〉0．05）。结论氨磺必利与利培酮治疗精神分裂症疗效均显著，安全性高。

Objective To compare the efficacy and safety between amisulpride and risperidone in the treatment of schizophrenia. Methods Sixty schizophrenics were randomly assigned to 2 groups of 30 ones each, they took orally amisulpride or risperidone for 6 months. Efficacies were assessed （PANSS）, the development states of adverse reactions with the Positive and Negative Syndrome Scale compared between 2 groups. Results After treat ment the PANSS scores of both groups lowered more significantly compared with pretreatment （P〈0. 01）, that was significantly lower in amisulpride than in risperidone group （P〈0.05） ; the incidence was respectively 13.3% in amisulpride and 36. 7% in risperidone group, which showed no significant group difference （P 〉0.05）. Conclusion Both amisulpride and risperidone have an evident effect and higher safety in the treatment of schizophrenia.